Known as Vestar Inc and based in California while the firm was SBIR involved, in the Spring 1995, a reverse merger between two biotech companies, NeXagen (drug discovery) acquired Vestar (liposomal drug delivery)k The two companies merged to form NeXstar Pharmaceuticals focused on cancer and inflammatory and immunological diseases. In 1999. the combined entity was then subsequently sold to Gilead Sciences, itself an SBIR company
